UNASSIGNED: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed to assess the effects of YXS tablets on exercise capacity and quality of life in patients with CHD. A total of 82 patients were included in this trial. Compared with the placebo group, the YXS group showed significant improvement in peak VO 2 (0.22 L/min vs 0.01 L/min; difference 0.1, 95% confidence interval (CI) 0.04-0.16, p = 0.000), peak Mets (0.58 vs 0.09; difference 0.3, 95% CI 0.12-0.47, p = 0.005), anaerobic threshold (AT) VO 2 (0.23 L/min vs 0.04 L/min; difference 0.12, 95% CI 0.07-0.18, p = 0.000), AT Mets (0.62 vs 0.16; difference 0.35, 95% CI 0.2-0.5, p = 0.001), and 6 minutes walking test (6MWT) (50.05 m vs 11.91 m; difference 29.92, 95% CI 18.78-41.07, p = 0.000). There were no differences in Hamilton anxiety rating scale (HAM-A score (1.97 vs 2.07; difference 2.03, 95% CI 0.99-3.06, p = 0.926) and Hamilton depression rating scale (HAM-D) score (1.06 vs 1.7; difference1.42, 95% CI 0.24-2.6, p = 0.592).
UNASSIGNED: In patients with CHD, YXS tablets, compared with placebo, could improve exercise capacity, without beneficial effects on anxiety and depression symptoms.
■随机,双盲,安慰剂对照,进行了多中心临床试验,以评估YXS片剂对CHD患者运动能力和生活质量的影响。共有82名患者被纳入该试验。与安慰剂组相比,YXS组显示峰值VO2的显着改善(0.22L/minvs0.01L/min;差异0.1,95%置信区间(CI)0.04-0.16,p=0.000),峰值大都会(0.58vs0.09;差异0.3,95%CI0.12-0.47,p=0.005),无氧阈值(AT)VO2(0.23L/minvs0.04L/min;差0.12,95%CI0.07-0.18,p=0.000),AT大都会(0.62vs0.16;差异0.35,95%CI0.2-0.5,p=0.001),和6分钟步行测试(6MWT)(50.05mvs11.91m;差异29.92,95%CI18.78-41.07,p=0.000)。汉密尔顿焦虑量表(HAM-A评分(1.97vs2.07;差异2.03,95%CI0.99-3.06,p=0.926)和汉密尔顿抑郁量表(HAM-D)评分(1.06vs1.7;差异1.42,95%CI0.24-2.6,p=0.592)无差异。
■在冠心病患者中,YXS片,与安慰剂相比,可以提高运动能力,对焦虑和抑郁症状没有有益的影响。